Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial

doi:10.1111/ajco.13753

	Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
	Liu, Jihong 2,3; Yin, Rutie 4,5; Wu, Lingying 6; Zhu, Jianqing 7; Lou, Ge 8; Wu, Xiaohua 9; Zhou, Qi 10; Gao, Yunong 11; Kong, Beihua 12; Lu, Xin 13
刊名	ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
	2022-03-31
关键词	BRCA mutation China olaparib ovarian cancer PARP inhibitor
ISSN号	1743-7555
DOI	10.1111/ajco.13753
通讯作者	Liu, Jihong(liujh@sysucc.org.cn)
英文摘要	Aim The phase III SOLO2 global study demonstrated the efficacy and safety of maintenance olaparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, in platinum-sensitive relapsed ovarian cancer patients with a BRCA mutation. This separate China cohort of SOLO2 investigated the efficacy and safety of maintenance olaparib in Chinese patients. Methods Patients received olaparib (300 mg twice daily, oral, tablets) or matched placebo. Primary endpoint was investigator-assessed progression-free survival (Response Evaluation Criteria in Solid Tumors version 1.1). Safety and tolerability were also assessed. Results Thirty-two patients were treated. Olaparib treatment led to an improvement in progression-free survival compared with placebo (hazard ratio = 0.44, 95% confidence interval: 0.17-1.19; median = 13.8 vs. 5.5 months). Results of secondary efficacy endpoints of time to first subsequent treatment/death and time to treatment discontinuation/death were consistent with progression-free survival results. Time to second progression/death and time to second subsequent treatment/death data were immature at data cutoff. The most common adverse events in the olaparib arm were nausea (81.8%), anemia (45.5%), and decreased appetite (36.4%). Grade >= 3 adverse events were experienced by 36.4% of olaparib and 10.0% of placebo patients. No adverse events led to discontinuation of treatment. There were six deaths (olaparib, five; placebo, one); one death in the olaparib arm was due to an unknown cause, all others were related to disease progression. Conclusions Efficacy and safety findings in the China SOLO2 cohort support the use of olaparib (300 mg twice daily) as maintenance treatment for Chinese patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.
资助项目	AstraZeneca ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, NJ, USA
WOS关键词	THERAPY
WOS研究方向	Oncology
语种	英语
出版者	WILEY
WOS记录号	WOS:000776130800001
资助机构	AstraZeneca ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, NJ, USA
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128293]
专题	中国科学院合肥物质科学研究院
通讯作者	Liu, Jihong
作者单位	1.Jilin Canc Hosp, Changchun, Peoples R China 2.Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, 651 Dongfeng E Rd, Guangzhou 510060, Peoples R China 3.Sun Yat Sen Univ, Dept Gynecol Oncol, Canc Ctr, Guangzhou, Peoples R China 4.Sichuan Univ, West China Univ Hosp 2, Dept Gynecol & Obstet, Chengdu, Peoples R China 5.Sichuan Univ, West China Univ Hosp 2, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Peoples R China 6.Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China 7.Univ Chinese Acad Sci, Dept Gynecol Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 8.Harbin Med Univ, Dept Gynecol Oncol, Canc Hosp, Harbin, Peoples R China 9.Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China 10.Chongqing Canc Hosp, Chongqing, Peoples R China
推荐引用方式 GB/T 7714	Liu, Jihong,Yin, Rutie,Wu, Lingying,et al. Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,2022.
APA	Liu, Jihong.,Yin, Rutie.,Wu, Lingying.,Zhu, Jianqing.,Lou, Ge.,...&Hsu, Kate.(2022).Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.
MLA	Liu, Jihong,et al."Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial".ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022).